3 citations
,
January 2023 in “International Journal of Molecular Sciences” Heat Shock Proteins are important in the development of Polycystic Ovarian Syndrome and could be targets for new treatments.
March 2011 in “European Urology Supplements” The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.
3 citations
,
December 2016 in “Canadian Urological Association journal” Men with more advanced male pattern baldness have a higher risk of prostate cancer and more severe disease.
April 2022 in “Diabetes Therapy” Low testosterone does not prevent prostate cancer in men with type 1 diabetes.
148 citations
,
May 2009 in “Molecular Pharmaceutics” Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.
July 2007 in “The Journal of Urology” Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.
13 citations
,
March 2022 in “JAMA Dermatology” Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.
61 citations
,
May 2010 in “Integrative Cancer Therapies” There is no clear recommendation for using selenium in cancer patients; it may be beneficial to correct low selenium levels before treatment.
3 citations
,
October 1995 in “Southern Medical Journal” Finasteride may cause breast enlargement, low testosterone a risk factor.
51 citations
,
September 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
October 1999 in “The Journal of Urology” New treatments and diagnostic methods for urological conditions show promise, but some lack sufficient accuracy for clinical use.
81 citations
,
February 2000 in “Anti-cancer drugs” Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
28 citations
,
January 2003 in “Urologic oncology” Suppressing certain hormones might help prevent prostate cancer.
April 2012 in “The Journal of Urology” Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.
April 2012 in “The Journal of Urology” Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.
65 citations
,
September 2017 in “British Journal of Cancer” Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.
57 citations
,
February 2007 in “International Journal of Cancer” A49T gene variant linked to higher prostate cancer risk, lower hormone levels, and slightly reduced balding risk.
30 citations
,
January 2008 in “The Aging Male” The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.
28 citations
,
December 2010 in “European Journal of Cancer” Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.
6 citations
,
January 2010 in “Neoplasma” Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.
35 citations
,
March 2012 in “The Journal of Sexual Medicine” Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
4 citations
,
June 2015 in “Journal of Genetics/Journal of genetics” Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.
November 2005 in “The Journal of Urology” Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
417 citations
,
February 2004 in “The Journal of Clinical Endocrinology and Metabolism” Testosterone therapy increases bone density in older men with low testosterone levels.
December 2023 in “International Journal of Molecular Sciences” Men with early balding showed higher levels of certain genes linked to hair loss and possibly prostate cancer.
32 citations
,
May 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
29 citations
,
October 1988 in “Journal of Steroid Biochemistry” Antiandrogens are effective for conditions like prostate cancer and skin issues, but more research is needed to confirm their benefits and minimize side effects.
9 citations
,
July 2018 in “Medicine” Men with vertex baldness may have a higher risk of developing prostate cancer, but more research is needed to confirm this.
1 citations
,
July 2010 in “Mayo Clinic Proceedings” The conclusion is that individualized treatment and proper medication use are crucial in men's health, with specific recommendations for ED, BPH, and prostate cancer management.